Brazil temporarily suspends use of the world’s first single-dose dengue vaccine after two reported deaths that health officials describe as suspicious. The suspension is announced by the health ministry and follows an adverse-reaction review involving people vaccinated between January and May. Authorities report that 501,044 people receive doses during that period, with 3,703 recipients (about 0.7%) developing symptoms similar to dengue and 42 people experiencing “more severe reactions.” Health officials say three severe cases are recorded, including the deaths of a 58-year-old man and a 48-year-old woman, while a 38-year-old woman is later discharged from intensive care. Health Minister Alexandre Padilha says there is not enough data to establish a cause-and-effect link between the vaccine and the serious outcomes, but he characterizes the pattern as a warning signal. The suspension is precautionary, with no immediate details on conditions for restarting vaccination. The vaccine was approved by Brazil’s health authorities in November and was developed in Brazil. Brazil says effects seen are not observed during earlier tests of more than 16,000 volunteers, and it notes the vaccine’s efficacy against severe dengue in trials. Brazil’s decision contrasts with the other dengue vaccine option, TAK-003, which requires two doses.
Brazil temporarily suspends single-dose dengue vaccine after two deaths
Brazil temporarily suspends use of the world’s first single-dose dengue vaccine after two reported deaths that health officials describe as suspicious. The suspension is announced by the health minist...
- Brazil temporarily suspends use of the first single-dose dengue vaccine after two deaths are reported as suspicious.
- Between January and May, 501,044 people are vaccinated, with 3,703 (about 0.7%) reporting symptoms similar to dengue.
- Health authorities report 42 people experience more severe reactions, including three severe cases.
- The deaths involve a 58-year-old man and a 48-year-old woman; a 38-year-old woman is later discharged from intensive care.
- Brazil says there is not enough data to confirm a cause-and-effect link and describes the suspension as precautionary.
RIO DE JANEIRO — Brazil said Monday it was temporarily suspending use of the world’s first single-dose dengue vaccine following two suspicious deaths. More than half a million people have received doses of the vaccine this year, which was developed publicly in Brazil and approved by health authorities in November. It is the first single-dose inoculation against the mosquito-borne dengue virus, which can cause high fever, headaches, muscle pain, nausea and rashes and in rare cases is fatal. READ: Dengue spreads fast in Brazil prompting emergency health measures Of the 501,044 people vaccinated between January and May, 3,703 — 0.7 […]...Keep on reading: Brazil suspends dengue vaccine following two deaths
2 months agoRIO DE JANEIRO, Brazil (AFP)—Brazil said Monday it was temporarily suspending use of the world's first single-dose dengue vaccine following two suspicious deaths. More than half a million people have received doses of the vaccine this year, which was developed publicly in Brazil and approved by health authorities in November. It is the first single-dose inoculation against the mosquito-borne dengue virus, which can cause high fever, headaches, muscle pain, nausea and rashes, and in rare cases is fatal. Of the 501,044 people vaccinated between January and May, 3,703 -- 0.7 per cent -- showed symptoms similar to dengue. Forty-two people, meanwhile, had "more severe reactions," according to the health ministry. Authorities have recorded three severe cases, including two that resulted in the deaths of a 58-year-old man and a 48-year-old woman. A 38-year-old woman entered intensive care but has since been discharged. "There is not enough data to establish a cause-and-effect link between the vaccine and these three serious cases, but it is a warning signal," Health Minister Alexandre Padilha told a press conference. As a precaution, "we have decided to temporarily suspend vaccination," he added, without elaborating on what would be required for it to be reintroduced. The minister said the "absolutely unexpected" effects had not been observed during tests on over 16,000 volunteers across 14 Brazilian states. Those trials had recorded an efficacy rate of 91.6 percent against the most severe form of the disease. The only other dengue vaccine, TAK-003, requires two doses taken three months apart, according to the World Health Organization (WHO). A single dose can help speed up and simplify mass vaccination campaigns. Brazil recorded more than 6,000 dengue deaths in 2024 -- nearly half of recorded deaths worldwide -- but the situation improved significantly last year.
2 months ago
FDA authorizes Abbott’s Libre Duo 10 Day wearable for continuous glucose and ketone monitoring
The U.S. Food and Drug Administration has authorized Abbott’s Libre Duo 10 Day Continuous Dual Glucose-Ketone Monitoring...
Nepal–Tibet flash floods and landslides kill over 350, hundreds still missing
Flash floods and landslides strike along the Nepal–Tibet border, killing more than 350 people, while many others remain...
Fisherman Hospitalized After Bear Attack During Colorado Fishing Trip
A fisherman in Colorado is hospitalized after a bear attacks him during a fishing trip, leaving him with severe injuries...